At a glance
| Abbreviation | HBV-D, chHBV, HBV-gor, HBV-A |
|---|---|
| ICTV species | Orthohepadnavirus hominoidei |
| Family | Hepadnaviridae |
| Baltimore class | VII — dsDNA-RT |
| Human infection | Human infection recorded; pattern not classified |
Also called: hepatitis B virus genotype D; chimpanzee hepatitis B virus; gorilla hepatitis B virus; hepatitis B virus genotype A; hepatitis B virus genotype B; hepatitis B virus genotype C; hepatitis B virus genotype E; hepatitis B virus genotype F; hepatitis B virus genotype G; hepatitis B virus genotype H; hepatitis B virus genotype I; hepatitis B virus genotype J and 7 more
Riboviria › Artverviricota › Revtraviricetes › Blubervirales › Hepadnaviridae › Orthohepadnavirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Riboviria |
|---|---|
| Kingdom | Pararnavirae |
| Phylum | Artverviricota |
| Class | Revtraviricetes |
| Order | Blubervirales |
| Family | Hepadnaviridae |
| Genus | Orthohepadnavirus |
| ICTV identifier | ICTV19910781 |
| NCBI taxon | 3431302 |
| Exemplar isolate | V01460 |
Host evidence
- human: 104,169 GenBank records
- pig: 10 GenBank records (flagged for review)
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
quote
1,769 hepatitis B-related deaths reported during 2023. ... newly reported chronic hepatitis B during 2023.
quote
The highest case fatality rate (0.4%) was seen for acute hepatitis B (18 deaths among 4257 cases).
quote
During 2023, 47 states and the District of Columbia reported 2,214 acute hepatitis B cases, corresponding to an estimated 14,400 infections after adjusting for case underascertainment and underreporting.
Lowest and highest vaccine effectiveness reported: 67% (van der Sande MA 2007 PLoS One; HBV infection (anti-HBc positivity) 15 years after infant vaccination, adolescents vaccinated in infancy) to 96.6% (van der Sande MA 2007 PLoS One; HBsAg carriage 15 years after infant vaccination, adolescents vaccinated in infancy). Two of 4 estimates, each from its own study; not a summary figure.
- Pooled or expert review
- Controlled observational
- Surveillance, ecological, modelling
What can follow the illness
quote
Approximately 25% of persons who become chronically infected during childhood and 15% of those who become chronically infected after childhood will die prematurely from cirrhosis or liver cancer.
quote
In the 2012-2013 survey (n=301), 5.5% (95% CI 3.4% to 9.0%) had significant liver fibrosis.
quote
The incidence of HCC was 55.5/100 000 carrier-years (95% CI 24.9 to 123.5).
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
- Clinical description: when it is observed to begin
- Product label observation window
- Compensation-table interval
Disease risk and vaccine efficacy: every estimate with its population, design and the sentence it came from.
Vaccines
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| Hepatitis B Vaccine (Recombinant) | See FDA listing | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-hepatitis-b-vaccine-recombinant (targetDisease 'Hepati |
| Hepatitis B Vaccine (Recombinant), Adjuvanted | See FDA listing | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-hepatitis-b-vaccine-recombinant-adjuvanted (targetDise |
| VAXELIS | MCM Vaccine Company | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-vaxelis (targetDisease 'Diphtheria / Tetanus / Pertuss |
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| Heplisav-B Injectable Product, 2-dose regimen | Mercy Medical Center | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT04588077 | candidateId ctgov-heplisav-b-injectable-product-2-dose-regimen-mercy-m |
| 1018 ISS-HBsAg-Single | Dynavax Technologies Corporation | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT00498212 | candidateId ctgov-1018-iss-hbsag-single-dynavax-technologies-corporati |
| hepatitis B vaccine | Emergent BioSolutions | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT01311674 | candidateId ctgov-hepatitis-b-vaccine-emergent-biosolutions (targetDis |
| MVA-HBV low dose formulation | GlaxoSmithKline | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT03866187 | candidateId ctgov-chad155-hii-hbv-low-dose-formulation-glaxosmithkline |
Antivirals
| Name | Mechanism | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|
| EntecavirEntecavir | Reverse transcriptase inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 2b442999-71b5-88f6-e063-6394a90a9d6e · verified 2026-10-30 |
| Entecavir AnhydrousENTECAVIR | Reverse transcriptase inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 3ada45bd-97aa-4713-ad29-6e462668c108 · verified 2026-10-30 |
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Disease risk and vaccine efficacy — burden figures and trial results, each quoted from its source
- Hepatitis B vaccine — ingredients, schedule and reported side effects
- Vaccine pipeline — candidates listed under “Hepatitis B”
- Other Hepadnaviridae viruses
- Veterinary vaccines for this virus — animals, kept separate on purpose